April 19, 2022

AVM Biotechnology Founder and CSO to Present Company Information and Clinical Trial Progress at Life Science Innovation Northwest

Seattle - AVM Biotechnology – a clinical-stage company developing AVM0703, a small molecule that mobilizes endogenous gamma delta TCR$^+$ and invariant TCR$^+$ bispecific Natural Killer T-like cells, today announced that Founder and Chief Science Officer, Dr. Theresa Deisher, will provide an invited company presentation as well as a poster presentation at Life Science Innovation Northwest taking place April 20-21, at the Washington State Convention Center in Seattle. The oral presentation will feature a discussion of AVM0703, the company's lead asset, as well as a clinical update on the status of the WWRD Study: AVM0703 for the Treatment of Lymphoma and Leukemia (NCT04329728). Dr. Deisher's presentation is scheduled for Wednesday, April 20th at 11:20 AM in the Oncology and Immunology Session.

AVM0703 is a small molecule which triggers the production and release of endogenous bispecific gamma delta TCR$^+$ and invariant TCR$^+$ Natural Killer T-like cells (AVM-NKT). These naturally occurring amplified immune cells have unique properties and appear rapidly in the blood following a single dose of AVM0703 which can be administered in an infusion center. Preclinical data suggest even greater efficacy in conjunction with chemotherapy as well as potential in solid tumors and autoimmune disorders. AVM0703 offers advantages over existing oncology standard of care treatment as the AVM-NKT cells are induced in vivo and do not face the same challenges in manufacturing and supply as other cell therapies.

Dr. Deisher will provide a clinical update on the near completion of the safety portion of the company's pivotal clinical trial in treating "no-option" Relapsed /Refractory Non-Hodgkin's Lymphoma/Leukemia patients as well as startling results in a patient enrolled in the FDA-authorized Expanded Access or Compassionate Use Program. The drug has been generally well-tolerated with patients experiencing mild to moderate and self-limiting side effects.

The mission of AVM Biotechnology is to develop and deliver treatments which save lives and improve outcomes by unlocking the potential of the body's own immune system. The company has raised nearly $25M to date with approximately 20% from non-dilutive funding. They have recently been awarded a $1.6M Phase II SBIR grant from the National Institute of Diabetes and Digestive Kidney Disease to study the reversal and prevention of Type 1 Diabetes and an Intent to Fund letter from the National Cancer Institute for an additional $2M Phase II SBIR grant to further the existing clinical trial. AVM will be requesting Breakthrough Therapy Designation, an expedited FDA review and accelerated approval in Non-Hodgkin's Lymphoma (NHL) while simultaneously exploring the potential of AVM0703 in Type 1 Diabetes. Commercialization in NHL is planned for Q1 2024.

Life Science Innovation Northwest, the largest annual Life Science conference in the Pacific Northwest, brings together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and

feature some of the most compelling recent life science breakthroughs. Dr. Deisher is delighted to highlight the transformative work of AVM Biotechnology in this setting. To register, please visit Life Science Innovation Northwest 2022 | Life Science Washington.

For information on AVM Biotechnology, contact Jena Dalpez at jdalpez@avmbiotech.com or 206-906-9922 or via avmbiotech.com.

Forward Looking Statement

This contains certain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and they may be accompanied by words such as "could," "would," "may," "potentially," "suggest," "believes," "expects," "should," and similar words or expressions. These forward-looking statements reflect our current views as of the date this is published, and are subject to risks, uncertainties, assumptions, changes in circumstances, and other factors; drug development and commercialization are highly risky and early clinical results in animals or humans may not reflect the full results from later stage or larger scale clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause our actual results, performance, and expectations to differ materially from those expressed or implied by these statements, including statements about: future and ongoing drug development and timing; the applications of drugs to specific diseases; the potential for ongoing preclinical or clinical trial results; FDA or other regulatory findings and approvals; potential market opportunities; and the occurrence of future events or circumstances. There are risks and uncertainties involving and not limited to our ability to progress in our research and development efforts, complete clinical testing, achieve our expected results, commercialize our products, avoid infringement of patients, trademarks and other proprietary rights of third parties, protect products from competition, navigate the political environment, maintain sufficient capital and funding, avoid problems with our manufacturing processes, maintain our operations, and obtain regulatory approval to sell and market the drugs in the United States and elsewhere. The reader should not place any undue reliance on such forward-looking statements. We have no obligation to release publicly the results of any revisions to any of our forward-looking statements to reflect events or circumstances after the date these statements are made or to reflect the occurrence of unanticipated events, except as may be required by law.